CAPR News and Press, Capricor Therapeutics Inc. From 08/11/22

Shares of Capricor Therapeutics ( NASDAQ: CAPR ) on Thursday gained 16% to $5.24, after the clinical-stage biotech announced an update on its lead drug candidate and reported Q2 results. San Diego, Calif.-based CAPR's lead candidate is a cardiac cell therapy called CAP...

Capricor Therapeutics press release ( NASDAQ: CAPR ): Q2 GAAP EPS of -$0.29 misses by $0.03 . As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million, compared to approximately $34.9 million on Dece...

-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant Duchenne Muscular Dystrophy Patients Presented a...

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial ...

-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients- -HOPE-3 Builds on Positive Data Results from HOPE-2 Study Recently Published in The Lancet- SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NAS...

Capricor Therapeutics (NASDAQ:CAPR) announced one-year results from a mid-stage open-label extension study on Monday to indicate that its lead asset CAP-1002 led to statistically significant clinical benefits in non-ambulant patients with later-stage Duchenne muscular dystrophy (DMD). The OLE...

-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking Session at PPMD’s Annual Conference on Saturday June 25, 2022- ...

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Comp...

Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercia...

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Mar...